ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation
ROSE12 是一种新型的抗 CTLA-4 FcγR 结合增强型抗体，可被细胞外三磷酸腺苷激活，它能选择性地清除肿瘤调节性 T 细胞，并在不引起全身免疫激活的情况下发挥抗肿瘤功效。
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-013397
Hayashi, Hiroki; Tatsumi, Kanako; Katada, Hitoshi; Matsuda, Yutaka; Tsunenari, Toshiaki; Honda, Masaki; Nemoto, Takayuki; Shimizu, Shun; Miura-Okuda, Momoko; Ikuta, Yuri; Ito, Ami; Ogami, Chika; Kato, Chie; Kamimura, Masaki; Kibayashi, Tatsuya; Kubo, Chiyomi; Komatsu, Shunichiro; Komori, Yasunori; Shinozuka, Junko; Susumu, Hiroaki; Tanno, Honoka; Tomii, Yasushi; Nakagawa, Kenji; Nagano, Hiroaki; Nanami, Masahiko; Nishito, Yukari; Fujisawa, Nozomi; Matsushita, Tomochika; Michisaka, Saki; Yamazaki, Masaki; Yoshimoto, Moe; Wakatsuki, Hiroaki; Wakabayashi, Tetsuya; Wada, Naoko A; Ueda, Otoya; Konishi, Hiroko; Kashima, Kenji; Tanaka, Hiroshi; Endo, Mika; Kitazawa, Takehisa; Sakaguchi, Shimon; Kamata-Sakurai, Mika; Igawa, Tomoyuki
